These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

124 related articles for article (PubMed ID: 39168811)

  • 1. IgA nephropathy after long-term treatment with infliximab for Crohn's disease Crohn's disease, a review of two cases.
    Montero SS; Guix EM; Ausín MS; García FI; Gómez BL; Martinez-Rosero CV; Guerrero XYM; Zaldumbide EJR; Velasco MAP; Alvarez CL; Lopez AS; Kasabji GE
    Nefrologia (Engl Ed); 2024; 44(4):599-601. PubMed ID: 39168811
    [No Abstract]   [Full Text] [Related]  

  • 2. Swift Efficacy with Infliximab 4 Years after Initial Standard Induction Therapy Followed by Severe Delayed Infusion Reaction in Crohn's Disease.
    Chiba M; Tsuji T; Nakane K; Obara Y; Komatsu M
    Inflamm Bowel Dis; 2020 Jan; 26(1):e4. PubMed ID: 31697829
    [No Abstract]   [Full Text] [Related]  

  • 3. Discontinuation of Infliximab Therapy in Patients with Crohn's Disease.
    Buhl S; Steenholdt C; Brynskov J; Christensen KR; Dorn-Rasmussen M; Thomsen OØ; Bendtzen K; Klausen TW; Dahlerup JF; Thorsgaard N; Jahnsen J; Molazahi A; Pedersen N; Kjeldsen J; Almer S; Dahl EE; Vind I; Cannon AG; Marsal J; Sipponen T; Agnholt JS; Kievit HAL; Aure SL; Martinsen L; Meisner S; Hansen JM; Ainsworth MA
    NEJM Evid; 2022 Aug; 1(8):EVIDoa2200061. PubMed ID: 38319804
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Acute Tubulointerstitial Nephritis Associated with Infliximab in a Patient with Crohn's Disease.
    Ota M; Iwai H; Imai K; Kamiya M; Yoshihashi-Nakazato Y; Miyasaka N; Kohsaka H
    Intern Med; 2016; 55(10):1367-70. PubMed ID: 27181549
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Efficacy and safety of biosimilar CT-P13 compared with originator infliximab in patients with active Crohn's disease: an international, randomised, double-blind, phase 3 non-inferiority study.
    Ye BD; Pesegova M; Alexeeva O; Osipenko M; Lahat A; Dorofeyev A; Fishman S; Levchenko O; Cheon JH; Scribano ML; Mateescu RB; Lee KM; Eun CS; Lee SJ; Lee SY; Kim H; Schreiber S; Fowler H; Cheung R; Kim YH
    Lancet; 2019 Apr; 393(10182):1699-1707. PubMed ID: 30929895
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Gastrointestinal: An unusual opportunistic infection mimicking lymphoma in a patient receiving Infliximab for Crohn's disease.
    Ma MX; Parry J; Venugopal K; Jennings M
    J Gastroenterol Hepatol; 2017 Jun; 32(6):1131. PubMed ID: 28557200
    [No Abstract]   [Full Text] [Related]  

  • 7. Cutaneous Pseudolymphoma in a Patient With Crohn's Disease Under Infliximab: First Report.
    Carvalhana S; Gonçalves A; Velosa J
    J Clin Gastroenterol; 2016; 50(5):436-7. PubMed ID: 26974759
    [No Abstract]   [Full Text] [Related]  

  • 8. Laparoscopic ileocaecal resection versus infliximab for terminal ileitis in Crohn's disease: a randomised controlled, open-label, multicentre trial.
    Ponsioen CY; de Groof EJ; Eshuis EJ; Gardenbroek TJ; Bossuyt PMM; Hart A; Warusavitarne J; Buskens CJ; van Bodegraven AA; Brink MA; Consten ECJ; van Wagensveld BA; Rijk MCM; Crolla RMPH; Noomen CG; Houdijk APJ; Mallant RC; Boom M; Marsman WA; Stockmann HB; Mol B; de Groof AJ; Stokkers PC; D'Haens GR; Bemelman WA;
    Lancet Gastroenterol Hepatol; 2017 Nov; 2(11):785-792. PubMed ID: 28838644
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Letter: treatment with subcutaneous CT-P13 in Crohn's disease patients with intravenous infliximab failure.
    Caron B; Fumery M; Netter P; Peyrin-Biroulet L
    Aliment Pharmacol Ther; 2022 Feb; 55(4):508-509. PubMed ID: 35092046
    [No Abstract]   [Full Text] [Related]  

  • 10. Asymptomatic Parasitic Infection in a Crohn's Disease Patient on Anti-TNFα Therapy: An Alert for Our Patients?
    Cocca S; Guarino M; Cicala M
    J Crohns Colitis; 2016 Dec; 10(12):1455-1456. PubMed ID: 27208388
    [No Abstract]   [Full Text] [Related]  

  • 11. Long-term risk of infection in patients with Crohn's disease on anti-TNF treatment: A prospective single-center cohort study in China.
    Li Y; Shu HJ; Lu H; Yang H; Li J; Tan B; Qian JM
    J Dig Dis; 2017 Jul; 18(7):388-394. PubMed ID: 28644565
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Value Assessment and Quantitative Benefit-Risk Modelling of Biosimilar Infliximab for Crohn's Disease.
    Catt H; Bodger K; Kirkham JJ; Hughes DA
    Pharmacoeconomics; 2019 Dec; 37(12):1509-1523. PubMed ID: 31372948
    [TBL] [Abstract][Full Text] [Related]  

  • 13. [Treatment of Crohn's disease by infliximab. About 20 cases].
    Serghini M; Karoui S; Meknini M; Matri S; Kallel L; Fekih M; Boubaker J; Filali A
    Tunis Med; 2009 Sep; 87(9):579-82. PubMed ID: 20180377
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Active flare of IgA nephropathy during long-term therapy with anti-tumor necrosis factor-α antibody drugs for Crohn's disease: three case reports and literature review.
    Shimizu A; Tsuboi N; Haruhara K; Shirai I; Ogawa K; Miura A; Oshiro K; Ueda H; Yokote S; Okabe M; Sasaki T; Ikeda M; Yokoo T
    CEN Case Rep; 2024 Aug; 13(4):249-257. PubMed ID: 38032436
    [TBL] [Abstract][Full Text] [Related]  

  • 15. De-escalation of Infliximab Maintenance Therapy from 8- to 10-week Dosing Interval Based on Faecal Calprotectin in Patients with Crohn's Disease.
    Papamichael K; Karatzas P; Mantzaris GJ
    J Crohns Colitis; 2016 Mar; 10(3):371-2. PubMed ID: 26546496
    [No Abstract]   [Full Text] [Related]  

  • 16. Use of infliximab in the treatment of Crohn's disease in children and adolescents.
    Hyams JS
    J Pediatr Gastroenterol Nutr; 2001 Sep; 33 Suppl 1():S36-9. PubMed ID: 11685974
    [No Abstract]   [Full Text] [Related]  

  • 17. [Indications and results of infliximab in Crohn's disease].
    Karoui S; Boubaker J; Filali A
    Tunis Med; 2004 Dec; 82(12):1057-63. PubMed ID: 15822505
    [TBL] [Abstract][Full Text] [Related]  

  • 18. SAFETY PROFILE OF ANTI-TNF THERAPY IN CROHN'S DISEASE MANAGEMENT: A BRAZILIAN SINGLE-CENTER DIRECT RETROSPECTIVE COMPARISON BETWEEN INFLIXIMAB AND ADALIMUMAB.
    Bau M; Zacharias P; Ribeiro DA; Boaron L; Steckert Filho A; Kotze PG
    Arq Gastroenterol; 2017 Dec; 54(4):328-332. PubMed ID: 28954043
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Long-term durability of infliximab treatment in Crohn's disease and efficacy of dose "escalation" in patients losing response.
    Chaparro M; Panes J; García V; Mañosa M; Esteve M; Merino O; Andreu M; Gutierrez A; Gomollón F; Cabriada JL; Montoro MA; Mendoza JL; Nos P; Gisbert JP
    J Clin Gastroenterol; 2011 Feb; 45(2):113-8. PubMed ID: 21242747
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Large paraspinal abscess as a complication of infliximab therapy in Crohn's disease.
    Nithianandan N; Loftus MJ; Johnson PDR; Charles PGP
    BMJ Case Rep; 2019 Apr; 12(4):. PubMed ID: 31036734
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 7.